-
1 day ago | 
ajmc.com | Pearl Steinzor
New research to be presented at this year’s European Congress on Obesity (ECO), taking place May 11-14 in Malaga, Spain, reveals that a new diagnosis of type 2 diabetes (T2D) is associated with an increased risk of developing certain obesity-related cancers—most notably liver, pancreatic, and bowel cancer—while showing no significant link to others such as endometrial or postmenopausal breast cancer.
-
1 day ago | 
ajmc.com | Pearl Steinzor
Once known mainly for its role in bone health, vitamin D is now recognized as a powerful immune system modulator with the potential to prevent colorectal cancer (CRC), according to a study published in Nutrients.1 Acting through receptors on immune cells, vitamin D influences key processes like inflammation, T-cell activation, and tumor suppression.
-
1 week ago | 
ajmc.com | Pearl Steinzor |Kimberly Westrich
As a primary source of health insurance for working-age Americans, employers are uniquely positioned to address health inequities affecting their workforce and their families, according to a recent study by the National Pharmaceutical Council (NPC).
-
1 week ago | 
ajmc.com | Pearl Steinzor
Researchers have identified a concerning rise in colorectal and pancreatic adenocarcinoma among younger adults, especially those aged 15 to 34 years, highlighting an urgent need for earlier recognition and screening in younger populations.1 The retrospective cohort study is published in JAMA Network Open.
-
1 week ago | 
ajmc.com | Pearl Steinzor
On Tuesday, President Donald J. Trump signed an executive order aimed at lowering drug prices, which include reforms to the Medicare Drug Price Negotiation Program, promoting competition for high-cost prescription drugs, and improving pharmacy benefit manager (PBM) fee transparency.1“The American people deserve better,” wrote Trump in the order.
-
1 week ago | 
ajmc.com | Pearl Steinzor
Although federally qualified community health centers (FQHCs) could be key components in diversifying clinical trials for hypertension and type 2 diabetes (T2D), a new review reveals that their involvement in such research remains limited, with most participation occurring at the lowest levels of engagement.1This systematic review is published in JAMA Network Open.
-
1 week ago | 
dermatologytimes.com | Pearl Steinzor
Women with psoriasis may be more likely than men to discontinue biologic treatments, including newer options like IL-17 and IL-23 inhibitors, due to differences in treatment satisfaction and adverse events (AEs), according to one study.1The prospective, multicenter study is published in the Journal of Psoriasis and Psoriatic Arthritis.
-
1 week ago | 
ajmc.com | Pearl Steinzor
Housing instability may worsen outcomes for people with type 2 diabetes (T2D), according to a study.1 Researchers found that those with stable housing had modest but significant improvements in hemoglobin A1c (HbA1c), blood pressure, and cholesterol levels over time. This observational longitudinal cohort study is published in JAMA Network Open.
-
1 week ago | 
ajmc.com | Pearl Steinzor
Precision medicine is transforming the treatment landscape for hematologic and solid tumors. On March 6, 2025, experts highlighted breakthroughs in multiple myeloma, lung cancer, and chronic lymphocytic leukemia (CLL) at an Institute for Value-Based Medicine (IVBM) event in Tampa, Florida. The evening opened with a panel discussion on best practices for testing in multiple myeloma.
-
2 weeks ago | 
ajmc.com | Pearl Steinzor
Today, Johnson & Johnson announced promising new phase 3 data for icotrokinra (JNJ-2113), a first-in-class oral interleukin (IL)-23 receptor antagonist, showing that 75% of adolescents with moderate to severe plaque psoriasis achieved completely clear skin by week 24.1 Presented at the 2025 World Congress of Pediatric Dermatology annual meeting, the subgroup analysis from the ICONIC-LEAD (NCT06095115) trial marks the first registrational study to simultaneously evaluate systemic therapy in...
